Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

rPCI-24781 is an orally-bioavailable histone deacetylase inhibitor that is in multiple clinical trials. We are conducting a Phase I trial in patients with advanced solid tumors, a Phase I/II trial in sarcoma patients (in combination with doxorubicin, an anti tumor agent) and a Phase I/II trial  testing PCI-24781 in patients with relapsed or refractory Non-Hodgkin's lymphoma. Currently we are enrolling the final follicular lymphoma patients in the Phase II portion of this trial and expect to complete enrollment by Q4 of calendar 2011.  Our collaboration partner for ex-US development, Servier, has five Phase I and I/II trials ongoing in Europe in lymphomas and solid tumors.

Conference Call and Webcast DetailsThe Company will hold a conference call today at 4:30 p.m. EDT. To participate in the conference call, please dial 1-877-407-8133 for domestic callers and 1-201-689-8040 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at www.pharmacyclics.com.

For further questions please contact Ramses Erdtmann, VP Finance at: 408-215-3325

Non-Hodgkin's Lymphoma (NHL) Market There are significant and distinct areas of unmet medical need across the NHL subtypes.  Within the indolent lymphomas, we believe a need exists for active therapies that avoid the toxicities typically seen with conventional chemotherapies. Such active therapies are needed as part of effective combinations early in the course of treatment, and also as effective single-agent treatments later in the course of disease progression.  In particular, drugs which are well tolerated and which do not limit subsequent treatment options b
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... DUBLIN , May 06, 2015 Research ... announced the addition of the "Cannulas Market ... Femoral, Injector, Infusion, Venous, Microcannula), Material (Plastic, Metal) ... Global Forecast to 2020" report to their ... expected to grow at a CAGR of 5.6% ...
(Date:5/6/2015)... May 6, 2015  Membership in Medicare Supplement plans ... Healthcare Business Strategy report released by Mark Farrah ... Medigap or Med Supp plans, covered approximately 11.2 ... 5.2% increase from 2013. Between 2013 and 2014, ... covered lives.  Though UnitedHealth was the segment growth ...
(Date:5/6/2015)... , May 06, 2015 Research and Markets ... "Energy based Ablation Devices - Global Strategic Business Report" ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. Annual ... 2020. Also, a seven-year historic analysis is provided for these ...
Breaking Medicine Technology:Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 3
... Oct. 12 Cannabis Science, Inc. (OTC Bulletin Board: ... developing pharmaceutical cannabis products, is pleased to announce guidance ... Applications for its cannabis clinical trials. The Company is ... current shareholders for a new class of common shares ...
... 12 OXIS International, Inc., (OTC Bulletin Board: ... Cataldo, Chief Executive Officer, and Bernie Landes, President, will ... of the fastest growing investor and stock trading communities ... will be held on Tuesday, October 12, 2010, at ...
Cached Medicine Technology:Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock 2Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock 3Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock 4Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock 5Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock 6Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock 7OXIS International Executives Interviewed on StockGoodies.com Radio 2
(Date:5/6/2015)... the exclusive hospital of the Tampa Bay Buccaneers, Florida Hospital ... James Stadium for all the “Bucs Babies” celebrating their first ... the “Bucs Babies” program last year. , “It is ... those born at the Florida Hospitals here in our community, ... enjoyed my time participating in the festivities, interacting with the ...
(Date:5/6/2015)... 06, 2015 Imprivata ® (NYSE: ... CTO David Ting will lead a discussion about the ... security and user authentication challenges, during Citrix Synergy ... will focus on the benefits of creating a network ... providers and patients can share information. It will also ...
(Date:5/6/2015)... PA (PRWEB) May 06, 2015 A quality built ... for a functional yet practical way to raise chickens on a ... by Chicken Coop Condo, it will have a chicken tractor that ... will last for many years, as it is able to flex ... control which areas of the land are fertilized, and it will ...
(Date:5/6/2015)... 2014 (PRWEB) May 06, 2015 ... on behalf of MEBC, an Alliance Award for ... Software during FOCUS 2015, JDA’s annual user conference ... manufacturing, retail and wholesale distribution sectors. This award ... clients are receiving services that advance their supply ...
(Date:5/6/2015)... Prime Pacific Health Innovations, the ... announce a new series of universal, one-time-use speculum ... footprint while improving treatment efficacy and saving therapists ... the world’s first waste hose designed specifically for ... claims the company’s president, Mr. Delmar Vogel. , ...
Breaking Medicine News(10 mins):Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Imprivata to Lead Discussion about Patient and Provider Authentication Challenges and the Internet of Things in Healthcare during Citrix Synergy 2Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3
... transparency , , PITTSBURGH, ... its members with online physician quality information in an effort ... , , "Today, more people ... obtain the best care at the best price," said Dr. ...
... killer disease, scientists say , , MONDAY, Dec. 15 (HealthDay ... provide a new target for treating deadly pancreatic cancer, ... College of Medicine in Minnesota show the "Seven-In-Absentia-Homolog" (SIAH) ... gene that, in a mutated form, has been previously ...
... Health insurers lose billions each year: Failing to retain plan members ... , ... Orlando, FL (Vocus) December 15, 2008 -- ... a portfolio of technology-driven processes and personal touch points - designed ...
... Dec. 15 Visage Imaging(R),Inc., a wholly owned ... MRCY ), announced that it has received FDA ... release, Visage CS 3.1. This release brings,significant enhancements ... tools,and includes new optional Neuroradiology and Oncology applications. ...
... YONKERS, N.Y., Dec. 15 Consumers Union is ... is contemplating relaxing its fish-consumption advice for vulnerable ... women, nursing mothers and infants. The agency,s recommendation ... concern about the neurological and behavioral effects of ...
... Group, Inc. (OTC Bulletin Board: MBTG) a leader in ... Nutrition Market, announces financial results for the third quarter ended ... Net revenue for the third quarter of 2008 increased 660% ... The Company reduced its, reported net loss of ($1,342,300), ...
Cached Medicine News:Health News:Highmark Blue Cross Blue Shield Provides Online Physician Quality Information to Members 2Health News:Pancreatic Cancer May Have a New Foe 2Health News:ConnextionsHealth Introduces Member Transition Services to Assist Health Plans in Efforts to Retain Members During Life Cycle Changes 2Health News:ConnextionsHealth Introduces Member Transition Services to Assist Health Plans in Efforts to Retain Members During Life Cycle Changes 3Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 2Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 3Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 4Health News:CU Statement on FDA Position on Mercury From Fish Consumption 2Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 2Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 3
... imaging agent that is labeled with technetium ... and localization of regions of reversible myocardial ... infarction under exercise and rest conditions. Imaging ... or up to 4 hours after administration ...
Stainless Steel...
Triangle shape (3.0mm long) Tip with Sliding Inner Shaft, Squeeze Activates Shaft to Punch; overall length 130mm, in stainless steel...
Olive Shaped Tip Cannula With Straight Shaft; in stainless steel....
Medicine Products: